Home › Stock analysis › LXRX
Lexicon Pharmaceuticals (LXRX) Stock: Why It Rose
Updated Oct 19, 2026, 4:00 PM ET · closing price
What changed since yesterday
- Closed at $1.55, +1.97% vs the prior close of $1.52.
- Volume 1.72M shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Compare with peers today
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)
LXRX rises 2.0% to $1.55. Closed at $1.55, +1.97% vs the prior close of $1.52. Day range $1.51–$1.58, opened at $1.54.
Last close$1.55+1.97%
Day range1.51–1.58
Open1.55
Volume1.72M
52-week range1.10–2.68
Avg volume (20d)2.93M
LXRX daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — LXRX rises 2.0% to $1.55
- Closed at $1.55, +1.97% vs the prior close of $1.52. Day range $1.51–$1.58, opened at $1.54.
- Volume was 1.72M shares, 0.6x its 50-day average of 2.80M.
- Price is -24.2% vs its 50-day average ($2.05) and -17.1% vs its 200-day average ($1.87).
- 52-week range $1.10–$2.68; today's close sits at 28% of that range, 42.2% below the 52-week high.
Oct 16, 2026 — LXRX slides 7.9% to $1.52, a 6-month low
- Closed at $1.52, -7.88% vs the prior close of $1.65. Day range $1.52–$1.68, opened at $1.68.
- Volume was 2.01M shares, 0.7x its 50-day average of 2.86M.
- Price is -26.3% vs its 50-day average ($2.06) and -18.7% vs its 200-day average ($1.87).
- 52-week range $1.10–$2.68; today's close sits at 27% of that range, 43.3% below the 52-week high.
Oct 15, 2026 — LXRX jumps 3.1% to $1.65
- Closed at $1.65, +3.12% vs the prior close of $1.60. Day range $1.62–$1.68, opened at $1.63.
- Volume was 1.43M shares, 0.5x its 50-day average of 2.91M — lighter than usual.
- Price is -20.7% vs its 50-day average ($2.08) and -11.6% vs its 200-day average ($1.87).
- 52-week range $1.10–$2.68; today's close sits at 35% of that range, 38.4% below the 52-week high.
Oct 14, 2026 — LXRX dips 0.6% to $1.60, a 3-month low, 5 down days in a row
- Closed at $1.60, -0.62% vs the prior close of $1.61. Day range $1.56–$1.63, opened at $1.61.
- Volume was 1.90M shares, 0.6x its 50-day average of 2.95M.
- Price is -23.7% vs its 50-day average ($2.10) and -14.2% vs its 200-day average ($1.86).
- 52-week range $1.10–$2.68; today's close sits at 32% of that range, 40.3% below the 52-week high.
- That makes 5 straight losses.
Oct 13, 2026 — LXRX dips 2.4% to $1.61, a 3-month low, 4 down days in a row
- Closed at $1.61, -2.42% vs the prior close of $1.65. Day range $1.59–$1.66, opened at $1.65.
- Volume was 2.05M shares, 0.7x its 50-day average of 2.95M.
- Price is -23.8% vs its 50-day average ($2.11) and -13.6% vs its 200-day average ($1.86).
- 52-week range $1.10–$2.68; today's close sits at 32% of that range, 39.9% below the 52-week high.
- That makes 4 straight losses.
Oct 12, 2026 — LXRX dips 1.8% to $1.65, a 3-month low, 3 down days in a row
- Closed at $1.65, -1.79% vs the prior close of $1.68. Day range $1.61–$1.67, opened at $1.65.
- Volume was 2.03M shares, 0.7x its 50-day average of 2.97M.
- Price is -22.5% vs its 50-day average ($2.13) and -11.3% vs its 200-day average ($1.86).
- 52-week range $1.10–$2.68; today's close sits at 35% of that range, 38.4% below the 52-week high.
- That makes 3 straight losses.
Oct 9, 2026 — LXRX slides 4.5% to $1.68, a 3-month low
- Closed at $1.68, -4.55% vs the prior close of $1.76. Day range $1.67–$1.77, opened at $1.75.
- Volume was 2.07M shares, 0.7x its 50-day average of 2.98M.
- Price is -21.6% vs its 50-day average ($2.14) and -9.6% vs its 200-day average ($1.86).
- 52-week range $1.10–$2.68; today's close sits at 37% of that range, 37.3% below the 52-week high.
Oct 8, 2026 — LXRX ends flat (+0.0%) to $1.76
- Closed at $1.76, +0.00% vs the prior close of $1.76. Day range $1.70–$1.78, opened at $1.75.
- Volume was 3.32M shares, 1.1x its 50-day average of 2.96M.
- Price is -18.3% vs its 50-day average ($2.15) and -5.2% vs its 200-day average ($1.86).
- 52-week range $1.10–$2.68; today's close sits at 42% of that range, 34.3% below the 52-week high.
Oct 7, 2026 — LXRX rises 0.6% to $1.76
- Closed at $1.76, +0.57% vs the prior close of $1.75. Day range $1.71–$1.77, opened at $1.73.
- Volume was 1.10M shares, 0.4x its 50-day average of 2.99M — lighter than usual.
- Price is -18.8% vs its 50-day average ($2.17) and -5.0% vs its 200-day average ($1.85).
- 52-week range $1.10–$2.68; today's close sits at 42% of that range, 34.3% below the 52-week high.
Oct 6, 2026 — LXRX rises 0.6% to $1.75
- Closed at $1.75, +0.57% vs the prior close of $1.74. Day range $1.72–$1.78, opened at $1.75.
- Volume was 1.64M shares, 0.5x its 50-day average of 3.02M — lighter than usual.
- Price is -19.6% vs its 50-day average ($2.18) and -5.4% vs its 200-day average ($1.85).
- 52-week range $1.10–$2.68; today's close sits at 41% of that range, 34.7% below the 52-week high.
Oct 5, 2026 — LXRX slides 4.4% to $1.74, a 3-month low, 5 down days in a row
- Closed at $1.74, -4.40% vs the prior close of $1.82. Day range $1.72–$1.83, opened at $1.83.
- Volume was 2.72M shares, 0.9x its 50-day average of 3.00M.
- Price is -20.5% vs its 50-day average ($2.19) and -5.8% vs its 200-day average ($1.85).
- 52-week range $1.10–$2.68; today's close sits at 41% of that range, 35.1% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — LXRX ends flat (+0.0%) to $1.82, 4 down days in a row
- Closed at $1.82, +0.00% vs the prior close of $1.82. Day range $1.80–$1.87, opened at $1.85.
- Volume was 2.32M shares, 0.8x its 50-day average of 3.00M.
- Price is -17.2% vs its 50-day average ($2.20) and -1.3% vs its 200-day average ($1.84).
- 52-week range $1.10–$2.68; today's close sits at 46% of that range, 32.1% below the 52-week high.
- That makes 4 straight losses.
LXRX bull case vs bear case (from the data)
Bull case
- Annual revenue grew 440.6% in the latest fiscal year (SEC XBRL).
- Insiders made 25 open-market purchases in the last 12 months.
Bear case
- Price is -24.2% vs its 50-day average — short-term trend is down.
- Price is -17.1% vs its 200-day average — below the long-term trend line.
- Latest fiscal-year net income: loss of $50.34M.
- Share count up 22.4% in a year (dilution).
- High volatility: average daily move of 3.1% over 20 sessions.
LXRX latest news & SEC filings
Every SEC filing by or about LXRX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 6, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $692.00K (prior year $28.87M) (-97.6% vs Jun 30, 2025)
- Net income: -$31.77M (prior year $3.25M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.07 (prior year $0.01) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade LXRX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Jan 29, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.15% (largest 9.7%). That is a volatile stock.
- Liquidity: about 2.93M shares (≈$4.55M) trade per day on average.
- 52-week position: $1.55 vs a range of $1.10–$2.68 (28% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Raymond Debbane bought 2,000 shares on Feb 25, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 10-Q May 7, 2026.
- Share count: 444.96M shares outstanding (Aug 3, 2026), +22.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
LXRX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 1.55 | 1.58 | 1.51 | 1.55 | 1.72M |
| Oct 16, 2026 | 1.68 | 1.68 | 1.52 | 1.52 | 2.01M |
| Oct 15, 2026 | 1.63 | 1.68 | 1.62 | 1.65 | 1.43M |
| Oct 14, 2026 | 1.61 | 1.63 | 1.56 | 1.60 | 1.90M |
| Oct 13, 2026 | 1.65 | 1.66 | 1.59 | 1.61 | 2.05M |
| Oct 12, 2026 | 1.65 | 1.67 | 1.61 | 1.65 | 2.03M |
| Oct 9, 2026 | 1.75 | 1.77 | 1.67 | 1.68 | 2.07M |
| Oct 8, 2026 | 1.75 | 1.78 | 1.70 | 1.76 | 3.32M |
| Oct 7, 2026 | 1.73 | 1.77 | 1.71 | 1.76 | 1.10M |
| Oct 6, 2026 | 1.75 | 1.78 | 1.72 | 1.75 | 1.64M |
| Oct 5, 2026 | 1.83 | 1.83 | 1.72 | 1.74 | 2.72M |
| Oct 2, 2026 | 1.85 | 1.87 | 1.80 | 1.82 | 2.32M |
| Oct 1, 2026 | 1.86 | 1.87 | 1.81 | 1.82 | 2.27M |
| Sep 30, 2026 | 1.89 | 1.95 | 1.84 | 1.88 | 1.74M |
| Sep 29, 2026 | 1.92 | 1.94 | 1.80 | 1.88 | 3.95M |
| Sep 28, 2026 | 1.88 | 2.05 | 1.81 | 1.90 | 10.89M |
| Sep 25, 2026 | 1.87 | 1.93 | 1.77 | 1.80 | 3.05M |
| Sep 24, 2026 | 2.05 | 2.06 | 1.85 | 1.86 | 4.44M |
| Sep 23, 2026 | 2.17 | 2.17 | 2.02 | 2.06 | 3.17M |
| Sep 22, 2026 | 2.05 | 2.20 | 2.02 | 2.18 | 4.84M |
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (LXRX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in THE WOODLANDS, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1062822.
LXRX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Philippe Amouyal | Director | Jun 4, 2026 |
| Group S.A. Artal | Director | May 8, 2026 |
| International Management S.A. Artal | Director | May 8, 2026 |
| International S.C.A. Artal | Director | May 8, 2026 |
| Participations S.A R.L. Artal | Director | May 8, 2026 |
| Life Sci Master Fund Lp Avicenna | Director | Feb 12, 2026 |
| Life Sci Master Gp Llc Avicenna | Director | Feb 12, 2026 |
| Sam L Barker | Director | Jun 4, 2026 |
| Ivan Cheung | Director | Jun 4, 2026 |
| Raymond Debbane | Director | Jun 4, 2026 |
| Michael Exton | Chief Executive Officer | Mar 3, 2026 |
| Global Management, Llc Invus | Director | Feb 4, 2026 |
| Christopher J Sobecki | Director | Jun 4, 2026 |
| L.L.C. Siren, | Director | Feb 4, 2026 |
| Administratiekantoor Westend Stichting | Director | May 8, 2026 |
| Diane E. Sullivan | Director | Jun 4, 2026 |
| Judith L Swain | Director | Jun 4, 2026 |
| S.A. Westend | Director | May 8, 2026 |
| Amaury Wittouck | Director | May 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Scott M Coiante | SVP, Chief Financial Officer | Mar 3, 2026 |
| Brian T Crum | SVP, General Counsel & Secr. | Mar 3, 2026 |
| Lisa Defrancesco | SVP, IR and Corp Comm | Mar 3, 2026 |
| Michael Exton | Chief Executive Officer | Mar 3, 2026 |
| Suma Gopinathan | SVP, Discovery | Mar 3, 2026 |
| Craig B Granowitz | SVP, Chief Medical Officer | Mar 3, 2026 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | Mar 3, 2026 |
| Wendy Mcdermott | SVP, Human Resources | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 25, 2026 | Raymond Debbane | Buy | 2,000 | $1.49 |
| Feb 25, 2026 | Raymond Debbane | Buy | 2,000 | $1.49 |
| Feb 25, 2026 | Raymond Debbane | Buy | 2,000 | $1.49 |
| Feb 25, 2026 | Raymond Debbane | Buy | 2,000 | $1.49 |
| Feb 23, 2026 | Raymond Debbane | Buy | 100,000 | $1.47 |
| Feb 23, 2026 | Raymond Debbane | Buy | 100,000 | $1.47 |
| Feb 23, 2026 | Raymond Debbane | Buy | 100,000 | $1.47 |
| Feb 23, 2026 | Raymond Debbane | Buy | 100,000 | $1.47 |
| Feb 20, 2026 | Raymond Debbane | Buy | 100,000 | $1.48 |
| Feb 20, 2026 | Raymond Debbane | Buy | 100,000 | $1.48 |
| Feb 20, 2026 | Raymond Debbane | Buy | 100,000 | $1.48 |
| Feb 20, 2026 | Raymond Debbane | Buy | 100,000 | $1.48 |
| Feb 19, 2026 | Raymond Debbane | Buy | 50,000 | $1.44 |
| Feb 19, 2026 | Raymond Debbane | Buy | 50,000 | $1.44 |
| Feb 19, 2026 | Raymond Debbane | Buy | 50,000 | $1.44 |
LXRX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-50.34M | -0.14 | $-67.85M |
| Dec 31, 2024 | $6.00M | $-200.40M | -0.63 | $-178.78M |
| Dec 31, 2023 | $1.11M | $-177.12M | -0.80 | $-161.90M |
| Dec 31, 2022 | $0 | $-101.94M | -0.62 | $-88.85M |
| Dec 31, 2021 | $0 | $-87.76M | -0.60 | $-87.02M |
Latest balance sheet: total assets $250.06M, total liabilities $75.53M, cash $40.92M (as of Jun 30, 2026).
LXRX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $2.36 |
| May 7, 2026 | 8-K Item 2.02 (results) | $1.68 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $1.64 |
| Jan 29, 2026 | 8-K Item 2.02 (results) | $1.44 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.43 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $1.15 |
| May 13, 2025 | 8-K Item 2.02 (results) | $0.63 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $0.37 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $1.19 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on LXRX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.